{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T23:34:25Z","timestamp":1772667265566,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.clml.2022.09.004","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T02:03:15Z","timestamp":1664935395000},"page":"8-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Systematic Review on Second Treatment-Free Remission (TFR) Attempt in Chronic Myeloid Leukemia (CML): Can it be Applied in Clinical Practice?"],"prefix":"10.1016","volume":"23","author":[{"given":"Rafiye","family":"\u00c7ift\u00e7iler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet G.","family":"Ak\u0131n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeynep","family":"Erat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-0894","authenticated-orcid":false,"given":"A. Emre","family":"E\u015fkazan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2022.09.004_bib0001","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2022.09.004_bib0002","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2022.09.004_bib0003","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/10428194.2012.745525","article-title":"Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009","volume":"54","author":"Chen","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2022.09.004_bib0004","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.09.004_bib0005","article-title":"Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities","author":"Narl\u0131 \u00d6zdemir","year":"2022","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2022.09.004_bib0006","article-title":"Mechanism of treatment-free remission in patients with chronic myeloid leukemia revealed by a computational model of CML evolution","author":"Lai","year":"2022","journal-title":"bioRxiv"},{"issue":"6","key":"10.1016\/j.clml.2022.09.004_bib0007","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomized, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"The Lancet Oncol"},{"key":"10.1016\/j.clml.2022.09.004_bib0008","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.09.004_bib0009","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1038\/s41375-018-0264-0","article-title":"Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells","volume":"32","author":"Ross","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.09.004_bib0010","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.09.004_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"The Lancet Haematol"},{"key":"10.1016\/j.clml.2022.09.004_bib0012","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M17-1094","article-title":"Treatment-free remission after second-line nilotinib treatment in patients with chronic myeloid leukemia in chronic phase: results from a single-group, phase 2, open-label study","volume":"168","author":"Mahon","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clml.2022.09.004_bib0013","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study","volume":"144","author":"Ross","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2022.09.004_bib0014","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in imatinib-resistant or-intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2022.09.004_bib0015","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Andersson TM-L. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.09.004_bib0016","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11899-019-0496-8","article-title":"Treatment-free remission in CML: the US Perspective","volume":"14","author":"Guru Murthy","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2022.09.004_bib0017","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.09.004_bib0018","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2022.09.004_bib0019","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.09.004_bib0020","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.09.004_bib0021","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/bjh.16718","article-title":"Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells","volume":"191","author":"Irani","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.09.004_bib0022","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13235904","article-title":"Regulatory T cell as a biomarker of treatment-free remission in patients with chronic myeloid leukemia","volume":"13","author":"Fujioka","year":"2021","journal-title":"cancers (Basel)"},{"key":"10.1016\/j.clml.2022.09.004_bib0023","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjh.15858","article-title":"Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells","volume":"186","author":"Cayssials","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2022.09.004_bib0024","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamaoncol.2020.5774","article-title":"Assessment of outcomes after stopping tyrosine kinase inhibitors among patients with chronic myeloid leukemia: a nonrandomized clinical trial","volume":"7","author":"Atallah","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2022.09.004_bib0025","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?","volume":"32","author":"Richter","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2022.09.004_bib0026","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11899-021-00653-1","article-title":"Treatment-free remission: the new goal in CML therapy","volume":"16","author":"Atallah","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2022.09.004_bib0027","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2019.02.001","article-title":"The spectrum of musculoskeletal symptoms in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors","volume":"79","author":"Diab","year":"2019","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2022.09.004_bib0028","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41375-020-0867-0","article-title":"Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs","volume":"34","author":"Sharf","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.09.004_bib0029","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.3324\/haematol.2019.242891","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: when and for whom?","volume":"105","author":"Atallah","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2022.09.004_bib0030","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1002\/cncr.30885","article-title":"Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia","volume":"123","author":"Legros","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2022.09.004_bib0031","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2019-123719","article-title":"The TKI-free duration after a first discontinuation attempt that failed in CP CML patients is a predictive factor of TKI-free remission after a second attempt","volume":"134","author":"Legros","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.09.004_bib0032","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/hon.2896","article-title":"Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience","volume":"39","author":"Ureshino","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2022.09.004_bib0033","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood-2018-99-114656","article-title":"Second attempt of TKI discontinuation with dasatinib for treatment-free remission after failing first attempt with imatinib: treatment-free remission accomplished by dasatinib (TRAD) trial","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2022.09.004_bib0034","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/1535-7163.MCT-20-0336","article-title":"HLA polymorphisms are associated with treatment-free remission following discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemiaHLA polymorphisms predict TFR in CML","volume":"20","author":"Ureshino","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2022.09.004_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100817","article-title":"Patient-specific molecular response dynamics can predict the possibility of relapse during the second treatment-free remission attempt in chronic myelogenous leukemia","volume":"32","author":"Kim","year":"2022","journal-title":"Neoplasia"},{"key":"10.1016\/j.clml.2022.09.004_bib0036","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1182\/bloodadvances.2020003235","article-title":"Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel","volume":"5","author":"Pavlovsky","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2022.09.004_bib0037","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.09.004_bib0038","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41375-021-01205-5","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial","volume":"35","author":"Radich","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2022.09.004_bib0039","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502201686X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502201686X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:41:33Z","timestamp":1761871293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502201686X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S215226502201686X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2022.09.004","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review on Second Treatment-Free Remission (TFR) Attempt in Chronic Myeloid Leukemia (CML): Can it be Applied in Clinical Practice?","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2022.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}